$1.53 Billion
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.-
Total revenue in the last quarter.$-32.4 Million
Net income is all revenues minus all expenses including taxes and interest in the last quarter.$-2.3
Earnings per share is the amount of net income that is attributed to each single share outstanding.-
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).-11.37x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$-33 Million
Earnings before interest expenses and taxes in the last quarter.270
The number of full time employees.Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
BidaskClub upgraded shares of Intellia Therapeutics (NASDAQ:NTLA) from a hold rating to a buy rating in a research note released on Friday morning, BidAskClub reports. A number of other equities an...
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing…
